Medical Condition News

RSS

First Edition: May 10, 2010

Today's health policy headlines include the feature coverage of aspects of health reform implementation, including how "gradfathering" will be defined in regulations and the latest details on the early retiree reinsurance program.

10 May 2010

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

Cipher Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults.

10 May 2010

28% of crashes attributed to cell phone talking, texting while driving

The American Academy of Orthopaedic Surgeons (AAOS) has joined forces with the Orthopaedic Trauma Association (OTA) on a public service announcement (PSA) urging drivers to NEVER text while driving. Simply put, texting is a deadly distraction that can cause accidents, severe orthopaedic injuries or even death. Orthopaedic surgeons not only treat, but want to prevent accidental traumas.

10 May 2010

AngioDynamics introduces redesigned Centros self-centering chronic hemodialysis access catheter

AngioDynamics announced today it has achieved the national launch of the newly redesigned Centros self-centering, chronic hemodialysis access catheter.

10 May 2010

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

A team of University of California, San Diego School of Medicine researchers has discovered that common intestinal bacteria appear to promote tumor growths in genetically susceptible mice, but that tumorigenesis can be suppressed if the mice are exposed to an inhibiting protein enzyme.

10 May 2010

Negative impact of depression on glycemic control in type 2 diabetes patients

In this German prospective representative study of patients with type 2 diabetes, baseline depression predicted problems with medication adherence, problems with health-related behaviors, and unsatisfactory glycemic control at follow-up.

10 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents

10 May 2010

CE 3D US creates spatial view for hemodynamic and morphologic evaluation of focal liver tumors

Recently, contrast-enhanced (CE) ultrasound (US) appeared as an important modality to show the vascularity in the areas of interest, and has been used widely in clinical diagnosis of liver lesions. Three dimensional ultrasonography (3D US) allows three orthogonal planes to spatially demonstrate the features of subjects, which has been frequently used in fetal US.

10 May 2010

Majority of Americans concerned about skin cancer but still like tans

When it comes to tanning, dermatologists have long suspected that most people need an attitude adjustment. Now, results of a new survey by the American Academy of Dermatology (Academy) confirmed that the majority of people still idolize the bronzed look of a tan despite wanting to protect themselves from skin cancer.

10 May 2010

UT Southwestern offers advanced lung-cancer patients free screenings of tumors for genetic mutations

UT Southwestern Medical Center is the only site in North Texas participating in a national study that offers advanced lung-cancer patients free screenings of their tumors for genetic mutations, some of which might be targets for treatment with existing or experimental therapies.

10 May 2010

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease. The study aims to validate non-invasive approaches to monitor the progression and treatment of Duchenne, and holds potential to facilitate the development of promising new therapies for people with the disease.

10 May 2010

UT Southwestern researchers uncover core function of gene involved in Fragile X syndrome

Researchers at UT Southwestern Medical Center have discovered how the genetic mutation that causes Fragile X syndrome, the most common form of inherited mental retardation, interferes with the "pruning" of nerve connections in the brain. Their findings appear in the April 29 issue of Neuron.

10 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Depression, hostile behavior increase risk of mortality

This study conducted on a sample of 20,625 employees of the French national gas and electricity companies demonstrates that being depressed and hostile increases the mortality risk.

10 May 2010

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.

10 May 2010

Double mastectomy best for long-term prognosis of breast cancer

When Cedric Skillom's mother, Lynda, 55, was diagnosed with an aggressive form of breast cancer, he was devastated by the news, but he never imagined that the largest cancer killer of women would strike his own health.

10 May 2010

$Free online fracture-risk calculator$

Free online fracture-risk calculator

FRAX- is a free online fracture-risk calculator (http://www.shef.ac.uk/FRAX/) that has been developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases at the University of Sheffield, UK. More and more physicians around the world are using the tool as an aid in making informed treatment decisions in the course of a clinical assessment of their patients.

10 May 2010

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Patients treated with the Zilver® PTX™ Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX™ Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.

10 May 2010

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Results from the SPIRIT IV clinical trial, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium, were published today in the New England Journal of Medicine.

10 May 2010

Medical Condition News

First Edition: May 10, 2010

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

28% of crashes attributed to cell phone talking, texting while driving

AngioDynamics introduces redesigned Centros self-centering chronic hemodialysis access catheter

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

Negative impact of depression on glycemic control in type 2 diabetes patients

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

CE 3D US creates spatial view for hemodynamic and morphologic evaluation of focal liver tumors

Majority of Americans concerned about skin cancer but still like tans

UT Southwestern offers advanced lung-cancer patients free screenings of tumors for genetic mutations

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

UT Southwestern researchers uncover core function of gene involved in Fragile X syndrome

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Depression, hostile behavior increase risk of mortality

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Double mastectomy best for long-term prognosis of breast cancer

Free online fracture-risk calculator

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News